Imexpharm Stock

Imexpharm EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Imexpharm (IMP.VN) as of Jul 20, 2026 is 17.78. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 20.84 — a change of -14.67% (lower).

EV/EBIT

17.78

YoY

-14.67%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Imexpharm is 2026 17.78 . EV/EBIT (Enterprise Value to EBIT) of Imexpharm was 2025 20.84 . It decreases by -14.67% lower compared to the previous year.

The Imexpharm EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
4.93 base
Jan 1, 2020
6.15 base
Jan 1, 2021
22.20 base
Jan 1, 2022
14.01 base
Jan 1, 2023
10.83 base
Jan 1, 2024
18.17 base
Jan 1, 2025
17.48 base
Jan 1, 2026 (e)
10.54 base
YEARPRICE-TO-EBIT
2026 est 10.54
2025 17.48
2024 18.17
2023 10.83
2022 14.01
2021 22.20
2020 6.15
2019 4.93
2018 7.18
2017 8.03
2016 5.18
2015 3.62
2014 2.69
2013 1.77
2012 9.50
2011 9.82
2010 15.09
2009 21.39
2008 22.34
2007 55.88
2006 32.29
Access this data via the Eulerpool API
Get Free API Key

Imexpharm Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Imexpharm's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Imexpharm's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Imexpharm's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Imexpharm grows earnings faster than its peers.

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

EV/EBIT (Enterprise Value to EBIT) of Imexpharm is 17.78 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Imexpharm

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Imexpharm